The partnership will bring a highly effective and precise alternative to traditional radiation therapy for treating cancer and some noncancerous tumors, without many of the side effects that often accompany treatment.
Karim Budhwani, a materials science and engineering (MSE) and biomedical engineering (BME) graduate student, presented to the Alabama Commission for Higher Education (ACHE) on December 4, 2015 in Montgomery, Ala.
Many UAB physicians from a variety of specialties appear on the prestigious Newsweek Top Cancer Doctors 2015 list.
UAB researcher awarded first joint AACR- TNBC Foundation Career Development Award focused specifically on triple negative breast cancer.
Elevated PARP1 polymerase in HER2+ breast cancer may confer susceptibility to PARP inhibitor drugs.
Christopher Willey, M.D., Ph.D., receives a crucial ACS research grant to further his novel work on the MARCKS protein in relation to brain cancer.
Researchers at the University of Alabama at Birmingham have identified a strategy that highly aggressive brain tumor cells use to fuel their relentless expansion.
Yang’s research focuses on a new class of drug – PARP inhibitors – that interfere with a cancer cell’s ability to repair DNA damage, hastening cell death.